Table 1.

Prevalence and characteristics of the four polycystic ovary syndrome phenotypical groups.

Variablef	A		B		C		D
	OA + HA + PCOM		OA + HA		HA + PCOM		OA + PCOM
	n	± s.d.	n	± s.d.	n	± s.d.	n	± s.d.
PCOS Group n %	521	65.9	133	16.7	80	10.0	62	7.8
Age years
≤19	60	16.6 ± 2.0	–	–	–	–	–	–
20–24	104	22.4 ± 1.3	26	22.3 ± 1.4	20	22.2 ± 1.4	08	22.6 ± 1.7
25–29	191	27.1 ± 1.3	49	27.3 ± 1.3	37	27.1 ± 1.2	23	26.7 ± 1.1
30–34	129	31.7 ± 1.3	38	31.2 ± 1.4	17	31.9 ± 1.3	24	31.6 ± 1.3
35–39	37	36.4 ± 1.2	20	36.3 ± 1.3	06	37.3 ± 1.0	07	36.2 ± 1.6
All ages	521	27.3 ± 5.0	133	27.3 ± 5.9	80	26.6 ± 5.2	62	28.8 ± 4.6
SBP (mmHg)	455	120 ± 12	144	116 ± 11	81	120 ± 11	58	116 ± 11
DBP (mmHg)	455	76 ± 9	144	75 ± 9	81	77 ± 8	58	74 ± 9
BW (kg)	477	74 ± 17	148	73 ± 17	87	72 ± 15	60	71 ± 16
BMI (kg/m2)	450	28.8 ± 6.4	135	28.0 ± 6.6	80	28.0 ± 6.2	54	27.97 ± 5.6
WC (cm)	426	86 ± 14	130	84 ± 15	78	83 ± 14	55	84 ± 13
WHR ratio	425	0.8 ± 0.1	130	0.7 ± 0.07	77	0.7 ± 0.07	55	0.7 ± 0.1
Testosterone (nmol/L)	440	1.9 ± 0.1	130	1.7 ± 0.1	77	1.9 ± 0.1	64	1.0 ± 0.4a,b
A4 (nmol/L)	405	9.3 ± 0.6	129	8.1 ± 0.5	74	9.6 ± 0.6	64	5.5 ± 1.8a,b,c
DHEAS (µmol/L)	329	4.9 ± 2.4	111	5.2 ± 2.6	63	5.8 ± 2.6	47	3.7 ± 1.4c,d,e
FAI (%)	388	6.3 ± 0.8	114	4.6 ± 2.1	67	6.1 ± 0.8	64	2.2 ± 0.2a,b,c

ANOVA followed by Tukey post hoc test: ^aA vs D, P < 0.001; ^bB vs C, P < 0.001; ^cC vs D, P < 0.001; ^dA vs C, P = 0.002; ^eB vs D, P = 0.001.

^fSBP, systolic blood pressure; DBP, diastolic blood pressure; BW, body weight; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; Testosterone, total testosterone; A4, androstenedione; DHEA, dehydroepiandrosterone; FAI, free androgen index; OA, oligo/anovulation; HA, clinical and/or biochemical hyperandrogenism; PCOM, polycystic ovary morphology; A, oligo/anovulation, hyperandrogenism, polycystic ovary morphology; B, oligo/anovulation, hyperandrogenism; C, hyperandrogenism, polycystic ovary morphology; D, oligo/anovulation, polycystic ovary morphology.